Taysha Gene Therapies Statistics
Share Statistics
Taysha Gene Therapies has 204.94M shares outstanding. The number of shares has increased by 9.58% in one year.
| Shares Outstanding | 204.94M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 153.61M |
| Failed to Deliver (FTD) Shares | 5.00K |
| FTD / Avg. Volume | 0.11% |
Short Selling Information
The latest short interest is 21.88M, so 10.68% of the outstanding shares have been sold short.
| Short Interest | 21.88M |
| Short % of Shares Out | 10.68% |
| Short % of Float | 14.25% |
| Short Ratio (days to cover) | 3.66 |
Valuation Ratios
The PE ratio is -1.84 and the forward PE ratio is -5.33.
| PE Ratio | -1.84 |
| Forward PE | -5.33 |
| PS Ratio | 13.3 |
| Forward PS | 12 |
| PB Ratio | 2.74 |
| P/FCF Ratio | -2.56 |
| PEG Ratio | n/a |
Enterprise Valuation
Taysha Gene Therapies Inc. has an Enterprise Value (EV) of 122.25M.
| EV / Earnings | -1.1 |
| EV / Sales | 7.91 |
| EV / EBITDA | -1.16 |
| EV / EBIT | -1.69 |
| EV / FCF | -1.52 |
Financial Position
The company has a current ratio of 4.08, with a Debt / Equity ratio of 0.54.
| Current Ratio | 4.08 |
| Quick Ratio | 4.08 |
| Debt / Equity | 0.54 |
| Total Debt / Capitalization | 35.09 |
| Cash Flow / Debt | -1.8 |
| Interest Coverage | -14.49 |
Financial Efficiency
Return on equity (ROE) is -1.49% and return on capital (ROIC) is -53.25%.
| Return on Equity (ROE) | -1.49% |
| Return on Assets (ROA) | -0.65% |
| Return on Capital (ROIC) | -53.25% |
| Revenue Per Employee | 297.13K |
| Profits Per Employee | -2.15M |
| Employee Count | 52 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 7.19% in the last 52 weeks. The beta is 0.41, so Taysha Gene Therapies 's price volatility has been higher than the market average.
| Beta | 0.41 |
| 52-Week Price Change | 7.19% |
| 50-Day Moving Average | 2.07 |
| 200-Day Moving Average | 2.37 |
| Relative Strength Index (RSI) | 36.69 |
| Average Volume (20 Days) | 4.49M |
Income Statement
In the last 12 months, Taysha Gene Therapies had revenue of 15.45M and earned -111.57M in profits. Earnings per share was -0.96.
| Revenue | 15.45M |
| Gross Profit | 15.45M |
| Operating Income | -72.44M |
| Net Income | -111.57M |
| EBITDA | -105.20M |
| EBIT | -72.44M |
| Earnings Per Share (EPS) | -0.96 |
Balance Sheet
The company has 143.94M in cash and 61.11M in debt, giving a net cash position of 82.83M.
| Cash & Cash Equivalents | 143.94M |
| Total Debt | 61.11M |
| Net Cash | 82.83M |
| Retained Earnings | -513.01M |
| Total Assets | 180.22M |
| Working Capital | 132.22M |
Cash Flow
In the last 12 months, operating cash flow was -73.02M and capital expenditures -7.37M, giving a free cash flow of -80.39M.
| Operating Cash Flow | -73.02M |
| Capital Expenditures | -7.37M |
| Free Cash Flow | -80.39M |
| FCF Per Share | -0.69 |
Margins
Gross margin is 100%, with operating and profit margins of -468.83% and -722.06%.
| Gross Margin | 100% |
| Operating Margin | -468.83% |
| Pretax Margin | -722.06% |
| Profit Margin | -722.06% |
| EBITDA Margin | -680.84% |
| EBIT Margin | -468.83% |
| FCF Margin | -520.27% |
Dividends & Yields
TSHA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -58.54% |
| FCF Yield | -23.99% |
Analyst Forecast
The average price target for TSHA is $7, which is 326.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 326.8% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | -2.42 |
| Piotroski F-Score | 2 |